Last updated: October 29, 2026
Bricanyl is a mature terbutaline brand with limited standalone financial disclosure, broad international availability, and substantial generic competition. Its commercial trajectory is driven by product age, low-cost substitution, declining use of oral and injectable beta-agonists, and competition from inhaled corticosteroid and long-acting bronchodilator therapies. AstraZeneca does not report Bricanyl revenue as a separate line item, so its current sales and profitability cannot be quantified from public company filings.
What is Bricanyl and which company markets it?
Bricanyl is a brand of terbutaline, a selective beta-2 adrenergic agonist used to relieve bronchospasm. Depending on jurisdiction, products have been marketed as inhalation solutions, metered-dose or dry-powder inhalers, tablets, and injectable formulations.
Terbutaline products are used in asthma and other obstructive airway diseases. Some jurisdictions have also permitted injectable terbutaline for acute bronchospasm. Use of beta-agonists in obstetrics has faced restrictions because of cardiovascular risks associated with prolonged administration.
| Product characteristic |
Bricanyl position |
| Active ingredient |
Terbutaline, usually as terbutaline sulfate |
| Pharmacologic class |
Short-acting beta-2 agonist |
| Principal uses |
Bronchospasm and asthma symptom relief |
| Original commercial owner |
AstraZeneca and predecessor companies |
| Main dosage forms |
Inhaled, oral, and injectable products, depending on country |
| Regulatory status |
Marketed in selected countries; status varies by formulation and jurisdiction |
| U.S. brand status |
Bricanyl is not a major current U.S. branded product |
| Competition |
Generic terbutaline and other short-acting bronchodilators |
| Patent profile |
Primarily legacy composition, formulation, and use rights; core protection is expired |
Bricanyl should be distinguished from AstraZeneca’s Symbicort, Pulmicort, and other respiratory products. Those products have had materially larger commercial franchises and are reported separately or within broader respiratory portfolios.
How large is the Bricanyl market?
There is no reliable public market-size figure for Bricanyl alone. Commercial databases may report country-level sales estimates, but AstraZeneca’s public filings do not identify Bricanyl as a separate revenue-generating brand.
The relevant market is the broader short-acting bronchodilator segment, where terbutaline competes with:
- Albuterol or salbutamol inhalers.
- Fenoterol products in selected countries.
- Levalbuterol or levosalbutamol.
- Ipratropium and combination bronchodilators.
- Inhaled corticosteroids used for disease control.
- Long-acting beta-2 agonists and fixed-dose inhaled combinations.
Salbutamol has a stronger global position in many markets because it is inexpensive, widely listed in treatment guidelines, and available through public procurement systems. Terbutaline remains commercially relevant in countries where Bricanyl or generic terbutaline has established formulary access.
Which markets are most important for Bricanyl?
Bricanyl’s commercial footprint is geographically fragmented. The brand has historically been marketed in Europe, Canada, Australia, parts of Asia, Latin America, the Middle East, and other international markets. Availability differs by dosage form.
The main geographic variables are:
- Whether terbutaline is included in national formularies.
- Whether inhaled or oral dosage forms are reimbursed.
- The degree of generic substitution.
- Local preference for salbutamol.
- Hospital procurement practices.
- Regulatory restrictions on oral or injectable beta-agonists.
In the United States, terbutaline remains available in generic forms, including injection, but Bricanyl is not a major current U.S. retail brand. The U.S. market therefore provides limited direct support for Bricanyl brand economics.
What is Bricanyl’s financial trajectory?
Bricanyl is best classified as a mature, low-growth or declining pharmaceutical brand rather than a strategic growth asset. Its financial trajectory has four phases.
Launch and expansion
Bricanyl benefited from the expansion of inhaled bronchodilator therapy and the historical use of oral terbutaline. The brand had value through physician familiarity, international registrations, and multiple dosage forms.
Maturity
As asthma treatment moved toward inhaled delivery and disease-control therapy, the relative importance of oral terbutaline declined. Generic entry reduced pricing power in markets where substitution was permitted.
Portfolio rationalization
Large pharmaceutical companies have progressively reduced emphasis on older non-core brands. Products with low revenue, local regulatory maintenance costs, or limited strategic value may be transferred, licensed, discontinued, or retained only in selected markets.
Current mature-brand phase
Bricanyl’s current economics are likely concentrated in residual branded demand, hospital supply, tender contracts, and markets where the brand has regulatory or physician loyalty. Its earnings profile is constrained by:
- Low average selling prices.
- Generic competition.
- Mature clinical demand.
- Limited patent exclusivity.
- Regulatory costs across multiple countries.
- Competition from inexpensive salbutamol products.
- Shifts toward inhaled corticosteroid-containing treatment.
AstraZeneca’s annual reports disclose major respiratory products but do not provide a separate Bricanyl revenue series. This prevents a verified year-by-year calculation of brand sales, gross margin, or operating profit [1].
When did Bricanyl lose exclusivity?
Bricanyl’s core pharmaceutical protection is long expired. Terbutaline was developed decades ago, and the active ingredient is available from multiple generic manufacturers.
The relevant loss of exclusivity occurred through several layers:
| Protection layer |
Current commercial implication |
| Terbutaline active ingredient |
Expired; generic manufacture is permitted |
| Early pharmaceutical compositions |
Expired |
| Original inhaler and dosage-form rights |
Expired or commercially obsolete |
| Legacy method-of-use rights |
Generally expired or limited by jurisdiction |
| Later device or formulation patents |
May have existed for specific products, but do not create broad Bricanyl exclusivity today |
| Regulatory exclusivity |
No meaningful current new-drug exclusivity for the legacy brand |
No current broad patent barrier appears to prevent generic terbutaline entry. Exact patent protection depends on the country, dosage form, device, and product owner. The absence of a current U.S. Bricanyl brand franchise also means that Orange Book patent disputes are not a central commercial issue for the brand.
What is the Orange Book status of Bricanyl?
Bricanyl is not a major current Orange Book-listed reference product in the United States. U.S. terbutaline products are primarily associated with generic approvals and legacy product records rather than an active Bricanyl branded franchise.
The FDA Orange Book is relevant to U.S. generic substitution and patent certification, but it does not provide a current patent shield for Bricanyl as a global brand. Any Paragraph IV challenge would depend on a specific listed reference product and an unexpired patent. The mature age of terbutaline makes a commercially meaningful Paragraph IV dispute unlikely for the original Bricanyl franchise [2].
Are there formulation patents protecting Bricanyl?
The most commercially relevant intellectual property historically concerned dosage forms, inhaler systems, delivery mechanisms, and manufacturing processes rather than the terbutaline molecule itself.
Potential protection categories included:
- Dry-powder inhaler formulations.
- Metered-dose inhaler systems.
- Nebulizer solutions.
- Stabilized terbutaline compositions.
- Device-dose metering systems.
- Manufacturing and particle-engineering processes.
- Combination products containing terbutaline and other bronchodilators.
These rights, where they existed, were generally product-specific and time-limited. They did not preserve broad exclusivity over terbutaline. A generic manufacturer can often avoid an expired formulation claim by using a different excipient system, device, concentration, or manufacturing process.
Current manufacturing barriers are therefore practical rather than patent-based. They include regulatory approval, validated analytical methods, device compatibility, sterile manufacturing for injectable products, reliable active pharmaceutical ingredient supply, and compliance with good manufacturing practices.
Which companies compete with Bricanyl?
Bricanyl competes against both terbutaline generics and alternative bronchodilator brands.
| Competitor category |
Examples |
Competitive effect |
| Generic terbutaline |
Multiple regional manufacturers |
Direct price competition |
| Salbutamol/albuterol |
Ventolin and generic products |
Stronger global substitution pressure |
| Levalbuterol |
Xopenex and generic products in the U.S. |
Alternative short-acting beta-agonist |
| Fenoterol |
Regional brands and generics |
Market-specific substitution |
| Ipratropium |
Atrovent and generics |
Alternative bronchodilator mechanism |
| Inhaled corticosteroids |
Budesonide, beclomethasone, fluticasone |
Disease-control competition |
| Combination inhalers |
Budesonide/formoterol, fluticasone/salmeterol and others |
Treatment migration away from rescue-only therapy |
Salbutamol is the most important direct commercial comparator in many jurisdictions. It has broad guideline recognition, extensive generic supply, and strong public-sector procurement penetration.
How does Bricanyl compare with salbutamol?
Bricanyl and salbutamol are both short-acting beta-2 agonists, but salbutamol has a stronger global commercial position.
| Factor |
Bricanyl |
Salbutamol |
| Active ingredient |
Terbutaline |
Salbutamol/albuterol |
| Patent status |
Mature and expired |
Mature and expired |
| Global availability |
Broad but uneven |
Very broad |
| Generic competition |
High |
Very high |
| Brand strength |
Regional |
Stronger global recognition |
| Guideline presence |
Varies by country |
Broad |
| Pricing power |
Low |
Low |
| Growth outlook |
Flat to declining |
Mature, with persistent volume demand |
Bricanyl may retain local advantages through formulary history, physician familiarity, or supply relationships. Those advantages are commercial rather than patent-based.
What is the regulatory status of Bricanyl?
Regulatory status varies by product and jurisdiction. A Bricanyl inhaler approved in one country does not establish approval in another. The most important regulatory issues are dosage form, route of administration, age indication, asthma labeling, and cardiovascular safety.
The FDA has approved generic terbutaline sulfate injection and has regulated terbutaline products under U.S. drug-safety requirements. The FDA has warned against prolonged use of terbutaline to prevent or treat preterm labor because of serious maternal cardiovascular risks. The agency has also stated that oral terbutaline should not be used for acute or maintenance treatment of asthma in place of inhaled therapy [3].
In Europe and other regulated markets, product information commonly identifies tremor, tachycardia, palpitations, hypokalemia, and other beta-agonist effects. These safety considerations restrict prolonged or inappropriate use and favor inhaled administration over systemic exposure [4].
Are biosimilars or generic launch risks relevant to Bricanyl?
Biosimilar risk is not relevant because Bricanyl is a small-molecule drug, not a biologic. The relevant threat is generic substitution.
Generic launch scenarios
A generic entrant can pursue several routes:
- Market a conventional terbutaline tablet or injection.
- Register a nebulizer solution.
- Develop an inhaled product using an alternative device.
- Enter through a hospital or government tender.
- Supply terbutaline as an active pharmaceutical ingredient.
- Acquire or license a legacy local brand.
The most credible commercial scenario is continued erosion of branded share rather than a single disruptive launch. The market is already structurally exposed to multiple generic suppliers.
What patent litigation and settlement agreements affect Bricanyl?
No major current patent litigation or settlement agreement materially affects the Bricanyl franchise based on publicly visible U.S. regulatory and company-disclosure records. The product’s age and lack of broad unexpired composition patents reduce the probability of new branded-generic litigation.
Historical disputes involving terbutaline, inhaler devices, or other respiratory products should not automatically be attributed to Bricanyl. Litigation must be tied to the exact product, patent, dosage form, and jurisdiction.
How strong is the Bricanyl patent estate?
Bricanyl has a weak current patent estate from a revenue-protection perspective.
| Patent-strength factor |
Assessment |
| Active ingredient protection |
None of current commercial significance |
| Broad composition claims |
Expired |
| Formulation protection |
Mostly expired or narrow |
| Device protection |
Potentially relevant only to specific legacy devices |
| Method-of-use protection |
Limited by age and jurisdiction |
| Generic design-around risk |
High |
| Litigation leverage |
Low |
| Geographic exclusivity |
None at the molecule level |
Bricanyl’s remaining defensibility is based on brand recognition, supply reliability, regulatory history, physician familiarity, and distribution relationships. Those assets can support residual sales but do not create durable exclusivity.
What is the investment and licensing outlook for Bricanyl?
Bricanyl is more likely to be treated as a portfolio-maintenance or divestiture asset than as a growth platform. A licensing transaction could be rational where a regional company values:
- Existing local registrations.
- Established hospital access.
- A recognized respiratory brand.
- Manufacturing rights.
- A bundle of mature products.
- Supply continuity in tender markets.
The likely transaction structure would involve geographic rights, a product transfer, or a mature-brand portfolio sale rather than a high-value global licensing deal. Valuation would depend on net sales, contribution margin, registration count, manufacturing obligations, and remaining product life, none of which are separately disclosed by AstraZeneca.
Key Takeaways
- Bricanyl is a mature terbutaline brand with no meaningful current molecule-level patent protection.
- AstraZeneca does not disclose standalone Bricanyl revenue.
- Generic terbutaline and salbutamol are the principal commercial threats.
- The market is more exposed to generic substitution than to biosimilar competition.
- U.S. Orange Book and Paragraph IV risk are limited for the legacy Bricanyl franchise.
- Regulatory restrictions on systemic terbutaline reduce the long-term role of oral and injectable formulations.
- Residual value may remain in regional brands, hospital tenders, local registrations, and supply relationships.
- Bricanyl’s financial trajectory is best characterized as mature, fragmented, and likely declining in branded terms.
FAQs About Bricanyl Market and Patent Risk
Is Bricanyl still available?
Bricanyl availability depends on country and formulation. Terbutaline products remain marketed in various jurisdictions, while specific Bricanyl presentations may have been discontinued, transferred, or replaced by generic products.
Is Bricanyl the same as Ventolin?
No. Bricanyl contains terbutaline. Ventolin contains salbutamol, called albuterol in the United States. Both are short-acting beta-2 agonists, but they are different active ingredients.
Can a generic company launch terbutaline without a Bricanyl license?
Generally, yes, if the generic product satisfies applicable regulatory requirements and does not infringe an unexpired country-specific patent. A license to the Bricanyl brand is not normally required to market generic terbutaline.
Does Bricanyl have orphan-drug protection?
Bricanyl is not generally associated with current orphan-drug exclusivity. Its active ingredient and principal therapeutic uses are established, non-orphan respiratory indications.
Is Bricanyl a growth opportunity for pharmaceutical investors?
Bricanyl is more consistent with a mature-brand or regional licensing opportunity than with a high-growth pharmaceutical investment. The principal value drivers are low-cost manufacturing, stable procurement demand, geographic rights, and operating efficiency rather than patent exclusivity.
References
-
AstraZeneca PLC. (2024). Annual report and Form 20-F 2023. AstraZeneca.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2011). FDA drug safety communication: New warnings against use of terbutaline to treat preterm labor. FDA.
-
European Medicines Agency. (n.d.). Terbutaline-containing medicinal products: Product information and regulatory records. EMA.
